Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates
Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers
Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions
Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates
Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates
DCx Biotherapeut
